Inozyme Pharma Reports Third Quarter 2021 Financial Results and Provides Business Highlights
November 09, 2021 16:05 ET
|
Inozyme Pharma Inc.
– On track to enroll patients in Phase 1/2 clinical trials in ENPP1 Deficiency and ABCC6 Deficiency in Q4 2021 and report preliminary biomarker and safety data in the first half of 2022 – – Cash,...
Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual Meeting
October 04, 2021 07:30 ET
|
Inozyme Pharma Inc.
- Natural History Study shows ectopic calcification and/or cardiovascular disease could serve as distinguishing characteristics of ENPP1 Deficiency in some children with rickets - - Preclinical data...
Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of...
Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights
August 11, 2021 06:00 ET
|
Inozyme Pharma Inc.
- Received Orphan Drug Designation from the European Medicines Agency for INZ-701 for the treatment of ABCC6 Deficiency – – Clinical Trial Application in Europe accepted for Phase 1/2 trial of...
Inozyme Pharma to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency
July 21, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human Resources
July 13, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency
June 09, 2021 07:30 ET
|
Inozyme Pharma Inc.
- Clinical trial initiation expected in mid-2021 –- Preliminary safety and biomarker data expected by the end of 2021 - BOSTON, June 09, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq:...
Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights
May 12, 2021 06:00 ET
|
Inozyme Pharma Inc.
– Filed Clinical Trial Application for INZ-701 for ABCC6 Deficiency in Europe; on track to initiate Phase 1/2 clinical trial in mid-2021 – – Published peer-reviewed preclinical data supporting...
Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency
May 07, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...